Form D/A — Imbria Pharmaceuticals, Inc.
0001104659-25-121539 · filed Dec 16, 2025
Figures are issuer-reported and describe stored filings. Data coverage and methodology.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- Rule 506(b)
- Reported offering amount
- $144,195,814
- Reported amount sold
- $66,695,817
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Imbria Pharmaceuticals, Inc.
- CIK
- 1745672
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- —
- Address
- 265 FRANKLIN STREET
BOSTON, Massachusetts 02110 - Phone
- 917-657-5069
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Alvin Shih · Executive OfficerBoston, Massachusetts Find on LinkedIn ↗
-
Andrew Levin · DirectorBoston, Massachusetts Find on LinkedIn ↗
-
Luse Rebecca · DirectorBoston, Massachusetts Find on LinkedIn ↗
-
Charles Dunn · DirectorBoston, Massachusetts Find on LinkedIn ↗
-
Komal Joshi · Executive OfficerBoston, Massachusetts Find on LinkedIn ↗
-
Pavan Cheruvu · DirectorBoston, Massachusetts Find on LinkedIn ↗
-
Ken Horne · DirectorBoston, Massachusetts Find on LinkedIn ↗
-
Zina Affas Besse · DirectorBoston, Massachusetts Find on LinkedIn ↗
Other filings from this issuer
View the original filing on SEC EDGAR ↗